Yoona Choi and Jung-Hyun Won attended the 65th Annual Meeting & Exposition of the American Society of Hematology (ASH), which took place from December 9 to 12, 2023, in San Diego, USA. Annually, the ASH conference brings together healthcare professionals, researchers, clinicians, and academics from around the globe to explore advancements in hematology. This prestigious event not only focuses on the study, diagnosis, treatment, and prevention of blood disorders but also features a variety of social events and opportunities for collaboration and the sharing of insights among experts in the field. Official photos from ASH are available here.

At the 'Outcomes Research—Lymphoid Malignancies: Poster II' session, Yoona Choi, serving as the first author and representing the entire research team, presented a study titled 'Evaluating the Effectiveness and Safety of Prephase Steroid Treatment before Remission Induction Chemotherapy in Pediatric Acute Lymphoblastic Leukemia: A Common Data Model-Based Real-World Data Approach.' This study investigated steroid pretreatment in pediatric acute lymphoblastic leukemia (ALL) patients undergoing remission induction chemotherapy (RIC), with the aim of reducing complications such as tumor lysis syndrome (TLS). Analyzing data from Seoul National University Hospital and Catholic University Seoul St. Mary’s Hospital, the study compared patients who received steroid pretreatment at least seven days before RIC with those who did not. The findings indicated a significant reduction in TLS incidence in the pretreated group. While overall survival rates were higher in this group, the difference was not statistically significant. These results provide important real-world evidence for the effectiveness of steroid pretreatment in reducing TLS risk in pediatric ALL patients.

This study was part of a larger project, funded by a grant from the Ministry of Health and Welfare, aiming to develop a disease registry database for pediatric ALL using real-world data in the clinical data warehouse (CDW) of Seoul National University Hospital and Catholic University Seoul St. Mary’s Hospital, thereby generating real-world evidence for pediatric ALL. 

Prof. Howard Lee gave a talk at an invited symposium in association with the Annual Conference of the Korean Society of Medical Informatics (KoSMI), held both online and offline on November 29, 2023. The title of his presentation was ‘Performance Increase of the Machine Learning Model to Predict Acute Coronary Syndrome in Patients with Type 2 Diabetes Mellitus by Replacing Binary Variables with Propesnsity Score’. This presentation was a culmination of a research project with the same title supported by the Seokcheon Foundation, 2023, where the current and former CCADD graduate students, namely David Seung U Lee, Jung-Hyun Won, and YeSol Hong collectively contributed by proposing a new novel way to address the falseness of binary feature in the electronic medical records. Prof. Lee's speech was well received by the audience evidenced by 6 follow-up questions! The more detailed methodological aspect of Prof. Lee' talk was presented in an accepted poster led by David Seung U Lee.  

Prof. Lee and David Seung U Lee met with Prof. M. Madan Babu, PhD, FRS, FMedSci, from St. Jude Children's Research Hospital, Memphis, TN, USA, July 17, 2023 in the Grand Hyatt Incheon. Prof. Babu is currently the Endowed Chair in Biomedical Data Science and Director of the Center of Excellence for Data Driven Discovery, St. Jude Children's Research Hospital. He will soon serve as a Senior Vice President and Chief Data Scientist at St. Jude Children's Research Hospital. Prof. Babu is an acclaimed researcher and scientist in various fields including GPCR signaling, regulation and pharmacology, gene , gene regulation, computational biology, structural bioinformatics, and drug discovery. He published many research articles in high-impact journals such as Nature, Science, and Cell. He is also Chief Editor for Molecular Systems Biology journal. 

It has turned out that Prof. Babu had followed the work from CCADD and is interested to know more about what is currently happening in those research areas. In this regard, the main purpose of Prof. Babu's visit this time was to establish professional relationships and set up international scientific bridges with St. Jude to enrich biomedical data science collaborations. Prof. Lee and David detailed the big data science and AI in drug development and optimal usage projects by CCADD, in which Prof. Babu showed great interest. Prof. Babu asked Prof. Lee for additional information and s for those research projects, which David will soon follow up. 

Out of a 3-hour lunch meeting with Prof. Babu, many collaboration opportunities and projects were discussed and proposed, one of which was an exchange program between the two institutions. Co-publication was also talked about, and Prof. Babu asked if CCADD could write a perspective paper regarding drug repurposing using AI for the Molecular Systems Biology journal. Prof. Lee and David hope to see more details soon and will keep CCADD informed. 

CCADD welcomes Le Dinh Tuan as a new researcher.

Tuan studied Computer Science at the University of Engineering and Technology, Vietnam National University. Afterward, he spent two years as a research assistant at the Multimedia Communication Signal Processing Lab (MCSP Lab) and received his master's from Artificial Intelligence Convergence Department, Pukyong National University. Tuan's research interests centere around statistical and machine learning (especially deep learning) methods for clinical data analysis.

As a researcher under the supervision of Professor Howard Lee, Tuan will actively partake in the current projects at CCADD pertaining to medical artificial intelligence. At the same time, he will seek to further his knowledge on applying the artificial intelligence technology to the fields of medicine and pharmaceutical sciences.

CCADD is thrilled to welcome Tuan to our team and looks forward to his contributions to our ongoing research efforts.

The 2023 Winter Internship at CCADD has begun. For this year’s internship, CCADD has Jaeho Hyun, who will study and experience the on-going research projects at CCADD.

Jaeho Hyun is a senior in biomedical engineering at Korea University. He studied mechanical system design engineering at Hongik University until the second year in college before he transferred to Korea University starting his junior year. His motivation for transfer was his interest in finding engineering solutions to solve problems in the medical field. Prior to this internship, he studied artificial intelligence (AI) technology in Seoul Information and communication technology (ICT) innovation square in the summer 2022. The program deepened his interest in applying technical knowledge to addressing real world problems pertaining to healthcare and medicine. During the internship at CCADD, he intends to expand his knowledge and explore various applications of real-world data analysis and AI technology in drug development sciences.

Jung-Hyun Won was invited to the KOREA AI SUMMIT 2022 (“AI for Good”), where she presented the collaboration research project between CCADD (Siun Kim, Jung-Hyun Won, David Seung U Lee, and Prof. Howard) and Microsoft Research Asia (MSRA) entitled “Revisiting and Reformulating Machine Learning-based Drug Repositioning”, orally and as a poster. The Korea AI Summit 2022, organized by AI Innovation Hub, Microsoft Research, IITP, and Korea University AI Research Institute, aimed to provide a platform for academic leaders from the prominent universities and institutes to share and explore the latest developments and technological trends in AI research.

Jung-Hyun Won stated that the team (i.e., CCADD and MSRA) has pointed out problems in the current task formulation of machine learning-based drug repositioning studies. According to Jung-Hyun Won, the team has found the spurious correlation between data collection pattern of drug characteristics and approved indications of drug. They also found that train-test split based on random sampling led to the overestimation of the performances of existing DR models. Jung-Hyun Won stressed that the team is currently reformulating drug repositioning problem as predicting investigational disease and generating eligibility criteria of clinical trials for a drug-disease pair.

Technology showcase can be watched the following youtube thumbnail.